Clinical trial · Observational
PelvEx 4: Advanced Pelvic Malignancy and the Role of the Multi-disciplinary Team Meeting
PelvEx 4: Advanced Pelvic Malignancy and the Role of the Multi-disciplinary Team Meeting - An International Assessment of MDT Decisions
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The treatment of locally advanced and recurrent rectal cancers is highly individualized to each patient and their pattern of disease, and this decision is often made at the Multidisciplinary Team (MDT) meeting . The PelvEx collaborative was designed with the intent to provide greater international consensus on appropriate treatment decisions for this cohort. However, we propose that international variation exists in how certain patients will be evaluated, assessed and ultimately treated despite having the same disease. We plan to measure this variation in order to provide a greater understanding of the differences that exist.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Locally Advanced Rectal Cancer | Malignant Rectal Neoplasm | CURATED_BROADER | 0.78 |
| Multidisciplinary Communication | — | UNRESOLVED | — |
| Multidisciplinary Team Meeting (MDT) | — | UNRESOLVED | — |
| Recurrent Rectal Cancer | Malignant Rectal Neoplasm | CURATED_BROADER | 0.78 |
| Treatment Decisions | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No specific intervention; cases are retrospective and patients have already been treated. | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Regional/geographic variation in MDT treatment allocations
- timeFrame
- Through study completion, an average of three months
- description
- Treatment consensus reached for each individual case
- measure
- Assessment of resectability
- timeFrame
- Through study completion, an average of three months
- description
- Was the malignancy felt to be resectable by MDT consensus at that institution
Secondary outcomes (1)
- measure
- Assessment of staging
- timeFrame
- Through study completion, an average of three months
- description
- Concordance between centres on the TNM staging of disease
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Complex case from participating PelvEx centre * Complete clinical information available to allow for informed MDT assessment * DICOM files for sharing of imaging related to treatment decisions
References
Publications (0)
Data not yet available